Kuzuya, T.; Kawabe, N.; Muto, H.; Wada, Y.; Komura, G.; Nakano, T.; Tanaka, H.; Nakaoka, K.; Ohno, E.; Funasaka, K.;
et al. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Curr. Oncol. 2024, 31, 4225-4240.
https://doi.org/10.3390/curroncol31080315
AMA Style
Kuzuya T, Kawabe N, Muto H, Wada Y, Komura G, Nakano T, Tanaka H, Nakaoka K, Ohno E, Funasaka K,
et al. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Current Oncology. 2024; 31(8):4225-4240.
https://doi.org/10.3390/curroncol31080315
Chicago/Turabian Style
Kuzuya, Teiji, Naoto Kawabe, Hisanori Muto, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka,
and et al. 2024. "Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma" Current Oncology 31, no. 8: 4225-4240.
https://doi.org/10.3390/curroncol31080315
APA Style
Kuzuya, T., Kawabe, N., Muto, H., Wada, Y., Komura, G., Nakano, T., Tanaka, H., Nakaoka, K., Ohno, E., Funasaka, K., Nagasaka, M., Miyahara, R., & Hirooka, Y.
(2024). Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Current Oncology, 31(8), 4225-4240.
https://doi.org/10.3390/curroncol31080315
